Paraproteinemias in Sjögren disease: cryoglobulinemia and serum monoclonal gammopathy identify distinct clinical phenotypes and differential lymphoma susceptibility Simone Longhino, Maria Teresa Rizzo, Valeria Manfrè, Giacomo Cafaro, Maria De Martino, Francesco Carubbi, Alessia Alunno, Nicoletta Del Papa, Paola Cipriani, Fabiola Atzeni, Onorina Berardicurti, Roberto Giacomelli, Serena Colafrancesco, Roberta Priori, Ludovica Manisera, Angelica Gattamelata, Serena Guiducci, Chiara Baldini, Elena Bartoloni, Luca Quartuccio Seminars in Arthritis and Rheumatism, 2026 • Isolated detectable serum monoclonal gammopathy, cryoglobulinemia, and their coexistence delineate distinct phenotypic subsets in Sjögren disease (SjD). • Cryoglobulinemia is linked with a predominant vasculitic phenotype. • The combination of cryoglobulinemia and monoclonal gammopathy is linked with high lymphoproliferative activity and lymphoma susceptibility. • SjD patients with both serum detectable monoclonal gammopathy and cryoglobulinemia require careful monitoring due to increased lymphoma risk. Sjögren disease (SjD) is a systemic autoimmune disease characterized by increased risk of B-cell non-Hodgkin lymphoma. Although cryoglobulinemia and serum monoclonal component (MC) are well-recognized paraproteinemias in SjD, no large-scale study has directly compared their isolated and combined impact on phenotype and lymphoproliferative risk. A retrospective, multicenter, cross-sectional study was conducted within the Italian GRISS registry. Patients with SjD were stratified into four groups: isolated monoclonal gammopathy (MC-alone), isolated cryoglobulinemia (CRYO-alone), both (MC+CRYO), or neither (controls). Demographics, lymphoma history, ever-documented ClinESSDAI domains, and laboratory lymphoproliferative risk-related markers were analyzed. Primary and secondary outcomes assessed lymphoma diagnosis and the distribution of laboratory lymphoproliferative risk-related markers and ClinESSDAI domains across groups, with associations tested using logistic regression adjusted for confounders. 1202 SjD patients were enrolled: 58 (4.83%) in the MC-alone, 32 (2.66%) in the CRYO-alone, 35 (2.91%) in the MC+CRYO, and 1077 (89.60%) controls. Compared with controls, only the MC+CRYO group showed significant association with lymphoma (OR 6.30, 95%CI 2.66–14.92; p<0.001), while MC-alone and CRYO-alone were not associated. Cryoglobulinemia, alone or combined with MC, correlated with laboratory lymphoproliferative risk-related markers such as rheumatoid factor (p<0.001) and low C4 (p<0.001), and with ClinESSDAI vasculitic features (cutaneous [p<0.001], renal [p<0.05], PNS [p<0.001]). The MC+CRYO group additionally displayed a lymphoproliferative phenotype correlating with constitutional (p<0.05), glandular (p<0.05), hematological (p<0.001), and lymphadenopathy (p<0.001) domains. Cryoglobulinemia in SjD associates with vasculitic disease activity, whereas the coexistence of serum MC and cryoglobulins identifies a distinct, high-risk subset characterized by advanced B-cell expansion and increased lymphoma susceptibility.
Increased Neutrophil-to-Lymphocyte Ratio as a Marker of Systemic Immunity in Lichen Sclerosus Alessia Paganelli, Alessandra Corrente, Roberta Priori, Giovanni Di Zenzo, Francesco Moro, Laura Colonna, Emanuele Scala, Giovanni Pellacani, Dario Didona Dermatology Practical and Conceptual, 2026 Introduction: Lichen sclerosus (LS) is a chronic inflammatory dermatosis traditionally considered a localized condition, yet associations with autoimmune comorbidities and circulating autoantibodies suggest possible systemic immune involvement. The neutrophil-to-lymphocyte ratio (NLR) is an inexpensive biomarker of systemic inflammation and frailty, but its role in LS has not been investigated. Aims: To evaluate NLR values in patients with LS and assess whether LS is associated with systemic inflammatory changes. Methods: This single-center retrospective observational study analyzed anonymized laboratory data from patients diagnosed with LS at IDI-IRCCS (Rome, Italy) between January 2020 and January 2025. Full blood count, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), age, and sex were collected. Patients were subdivided into three age groups (<65, 65–74, ≥75 years). Welch’s ANOVA and t-tests assessed group differences; chi-square tests examined NLR frailty-range distribution; Pearson correlations evaluated associations with CRP and ESR. Results: A total of 631 samples were included. Mean NLR was 2.34 ±1.36, increasing significantly with age (P=0.02). Approximately one third of patients fell within frailty-associated NLR ranges. Among adults <65 years, mean NLR (2.17 ±1.00) was significantly higher than in two healthy control cohorts (1.85 ± 0.64 and 1.65 ± 1.96; both P<0.01). NLR correlated moderately with ESR (r=0.47) and modestly with CRP (r=0.36). Conclusions: LS is associated with higher NLR values than those observed in healthy controls, indicating mild systemic inflammation. These findings support the concept that LS may not be exclusively localized but may involve broader immune dysregulation. NLR may help identify LS patients with potential systemic involvement, although prospective validation is required.
Heat-not-burn tobacco induces protein post-translational modifications and apoptosis in bronchial cells: possible role in rheumatoid arthritis Claudia Ciancarella, Federica Maria Ucci, Valeria Manganelli, Tina Garofalo, Elena Fasciolo, Roberta Priori, Fulvia Ceccarelli, Manuel Sergi, Camilla Montesano, Francesco Bartolini, Antonio Sili Scavalli, Fabrizio Conti, Maurizio Sorice, Cristiano Alessandri Rmd Open, 2026 Objectives Smoking is recognised as one of the strongest environmental risk factors for the development of rheumatoid arthritis (RA). Cigarette smoke increases protein post-translational modifications (PTMs), including citrullination and carbamylation, involved in the pathogenetic mechanisms of RA. Recently, tobacco companies developed new products, such as iQOS, a heat-not-burn cigarette (HNBC), which are becoming increasingly used. To date, only two epidemiological studies have been conducted in the rheumatology field. However, no studies are available on the effects of HNBCs on the pathogenic mechanisms involved in rheumatic diseases. We aimed to evaluate whether HNBCs are associated with an increase in PTMs and their effects on cell death mechanisms, such as apoptosis. Methods Human bronchial cells (BEAS-2B) were treated with cigarette smoke extracts from traditional cigarettes (TC) and HNBC. Western blot was performed to assess protein citrullination and carbamylation, while apoptosis was assessed by flow cytometry, after staining with annexin V-FITC/PI and western blot through enzyme Parp1 evaluation. Results The exposure of BEAS-2B to HNBC or TC extracts causes significantly increased citrullination and carbamylation of proteins, compared with untreated cells. Furthermore, it leads to an augmentation of apoptosis, evaluated through annexin V-FITC/PI and enzyme Parp1 levels. Conclusion Our results show that the extracts of HNBC and TC increase citrullination, carbamylation and influence cell death, causing an activation of apoptosis. This is the first study showing the effects of HNBC on PTMs and cell death mechanisms, raising alarm about the safety of these smoking alternatives in rheumatology. These data allow us to speculate that HNBC, like TC, could represent a risk factor for the development of RA in genetically susceptible individuals.
Clinical and serological differences of an Italian Sjögren’s disease cohort according to three geographic macro-area localisations Fabiola Atzeni, Maria Letizia Currò, Roberto Dal Pozzolo, Giacomo Cafaro, Valeria Manfrè, Luca Quartuccio, Francesco Carubbi, Alessia Alunno, Nicoletta Del Papa, Paola Cipriani, Onorina Berardicurti, Roberta Priori, Angelica Gattamelata, Serena Guiducci, Elena Bartoloni Clinical and Experimental Rheumatology, 2025 OBJECTIVES: The phenotype of Sjögren's disease (SjD) may be influenced by several variables. Among these, the role of patient geolocation has been poorly explored. The study compared epidemiologic, serologic, clinical features and comorbidities according to geographical origin in a large Italian multicentre SjD cohort. METHODS: This is a retrospective analysis of a multicentre SjD cohort (2016 ACR/EULAR criteria) consecutively included in the Italian SjD Study Group registry and grouped into three macrogeographic areas: North, Centre and South. Disease-specific epidemiologic, serologic, histologic and clinical variables were collected. Comorbidities, traditional cardiovascular (CV) risk factors and history of CV events were also recorded. All data were stratified by geographic area to assess regional differences. RESULTS: 1231 SjD patients, median 53 (42-63) years at diagnosis and 95% females, were included. No differences were observed in sex distribution or ethnicity among the three areas. Patients from the South had older age at diagnosis compared to the North (55 vs. 51 years, p=0.001) and Centre (55 vs. 51 years, p=0.002) and higher frequency of activity in the constitutional and articular but lower in biological domains (p<0.001 for all). Hypertension and hypercholesterolaemia were more prevalent in the Centre and obesity was more common in the South compared to the North (p<0.001). No significant differences were observed in other CV risk factors and CV events. CONCLUSIONS: This study provides the first evidence of geo-epidemiological differences among Italian SjD patients, highlighting how geographic origin is associated with disease phenotype and comorbidities. These regional disparities likely reflect environmental, socio-cultural and healthcare system-related factors, underscoring the need for personalised disease management strategies.
Sex disparities in the phenotype at diagnosis of Sjögren’s disease: artificial intelligence-driven characterisation in 17,416 patients Pilar Brito-Zerón, Alejandra Flores-Chávez, Ildiko Fanny Horváth, Roberta Priori, Hendrika Bootsma, Berkan Armagan, Luca Quartuccio, Sonja Praprotnik, Yasonuri Suzuki, Gabriela Hernandez-Molina, Vasco C. Romão, Agata Sebastian, Elena Bartoloni, Maureen Rischmueller, Roser Solans, Sandra G. Pasoto, Gunnel Nordmark, Isabel Sánchez Berná, Francesco Carubbi, Virginia Fernandes Moça Trevisani, Valeria Valim, Sheila Melchor, Brenda Maure Noia, Eva Fonseca-Aizpuru, Lucía Delgado, Hideki Nakamura, Miguel López-Dupla, Marcos Vazquez, Miriam Akasbi, Guillem Policarpo Torres, Borja De Miguel Campo, Rosana Rouco, Antónia Szántó, Angelica Gattamelata, Arjan Vissink, Levent Kilic, Valeria Manfrè, Katja Perdan Pirkmajer, Yuhei Fujisawa, Roberto Pereira da Costa, Piotr Wiland, Roberto Gerli, Chandra Kirana, Norma Nardi, Manuel Ramos-Casals Clinical and Experimental Rheumatology, 2025 OBJECTIVES: Sjögren disease (SjD) predominantly affects females, but the early disease presentation in male patients remains poorly characterised due to historically small sample sizes. The aim of this study was to investigate sex‑based differences in the clinical phenotype at diagnosis of SjD and identify predictors of patient sex using a large international cohort and AI‑enhanced analysis. METHODS: Cross-sectional analysis of an anonymised dataset comprising 17,416 worldwide patients fulfilling the 2002/2016 classification criteria (Sjögren Big Data Registry). We stratified the dataset by sex and conducted a comparative analysis of baseline glandular and systemic involvement, organ-specific ESSDAI domains, and immunological profiles. Multivariate logistic regression models were developed, adjusting for epidemiological confounders (age and ethnicity) to identify predictors of sex classification. We used a generative AI (OpenAI's GPT-4o model) environment with Python (version 3.9) and the pandas (1.4.3), numpy (1.21.5), and matplotlib (3.5.1) libraries. All analyses adhered to GDPR standards, with anonymized patient data and strictly controlled secure environments. RESULTS: The cohort included 1,161 (6.67%) men and 16,255 (93.33%) women, with a mean age at diagnosis of 51.11 years (SD=14.45). Men showed a higher mean age at diagnosis (54.09 vs. 51.42 years in women; t=6.08, p<0.0001), a higher average ESSDAI score (7.65 vs. 5.93; t=7.91, p<0.0001) and higher frequencies in severe DAS categories (i.e. high activity 20% vs. 12% in women, χ² = 81.15, p<0.0001). The epidemiologically-adjusted logistic regression model (pseudo R-squared value of 0.026) identified statistical significance for age (coefficient =0.009, p=0.024; each additional year in age increased the likelihood of being female by 1.4%), ethnicity (coefficient=0.579, HR=1.78, p=0.004), ocular dryness (coefficient=-0.607, HR=0.54, p<0.001), and systemic activity in the glandular (coefficient=0.359, HR=1.43, p=0.006) and pulmonary (coefficient=0.445, HR=1.56, p=0.004) ESSDAI domains. CONCLUSIONS: Male SjD patients present a distinct, more systemic phenotype at diagnosis. Awareness of sex‑specific features can improve early recognition and tailored management.
Immunological signatures in patients with Sjögren’s disease: association with systemic disease activity at diagnosis Lucía Delgado, Alejandra Flores-Chávez, Antónia Szántó, Roberta Priori, Heendrika Bootsma, Berkan Armagan, Luca Quartuccio, Sonja Praprotnik, Yasonuri Suzuki, Gabriela Hernandez-Molina, Vasco C. Romão, Agata Sebastian, Elena Bartoloni, Maureen Rischmueller, Roser Solans, Sandra G. Pasoto, Cecilia Fugmann, Isabel Sánchez Berná, Francesco Carubbi, Virginia Fernandes Moça Trevisani, Valeria Valim, Sheila Melchor, Brenda Maure Noia, Eva Fonseca-Aizpuru, Hideki Nakamura, Miguel López-Dupla, Marcos Vazquez, Miriam Akasbi, Guillem Policarpo Torres, Borja De Miguel Campo, Mihaela Roxana Suru, Carmen Vericat Queralt, Ildiko Fanny Horváth, Ilenia Fischetti, Arjan Vissink, Levent Kilic, Valeria Manfrè, Katja Perdan Pirkmajer, Yuhei Fujisawa, Matilde Bandeira, Krzysztof Proc, Roberto Gerli, Chandra Kirana, Norma Nardi, Manuel Ramos-Casals, Pilar Brito-Zerón Clinical and Experimental Rheumatology, 2025 OBJECTIVES: This study aimed to analyse the relationship between distinct autoantibody combinations (immunological signatures) and systemic disease activity in patients with Sjögren's disease (SjD). The hypothesis was that specific multi-autoantibody signatures would be associated with higher systemic disease activity at diagnosis, serving as predictors of a more severe disease course. METHODS: A retrospective observational study was conducted using data from the Big Data Sjögren Project Consortium, an international multicentre registry. The serological status (positive/negative) at diagnosis for ANA, RF, anti-Ro, and anti-La was recorded for each patient. Systemic disease activity was assessed using the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) and a simplified Disease Activity Score (DAS) categorised as low, moderate, or high. Statistical analyses included pairwise comparisons, a sensitivity analysis grouping signatures by the number of positive antibodies, and demographic-adjusted ordinal models. RESULTS: Serum autoantibodies were highly prevalent, with over 94% of patients having at least one autoantibody. The mean ESSDAI values varied significantly across signatures. The fully seronegative group had the lowest mean ESSDAI at 3.61, while the fully seropositive group (ANA+/Ro+/La+/RF+) had the highest among common phenotypes, with a mean of 7.93. A strong dose-response relationship was observed, with each additional positive autoantibody associated with a 1.11-point mean increase in ESSDAI and a 35% increase in the odds of being in a higher DAS category. The rarest signatures, such as ANA-/Ro-/La+/RF+, exhibited the highest mean systemic activity (mean 13.20). CONCLUSIONS: The number and combination of SjD-related autoantibodies at diagnosis are robustly associated with systemic disease activity. Multi-positive profiles, particularly those combining RF with anti-Ro, identify patients at higher risk of systemic activity. Interpreting combined serological patterns offers an immediate, low-cost method for patient stratification and can help guide clinical management.
Concurrence of mixed cryoglobulinaemia and cold agglutinin disease, and the putative role for a stereotyped immunoglobulin light chain Ylenia A. Minafò, Nicola Monaco, Valerio Fiorilli, Francesca La Gualana, Matteo D'Ambrosi, Chiara De Renzis, Stefania Basili, Maurizio Sorice, Serelina Coluzzi, Roberta Priori, Marcella Visentini, Fabrizio Conti, Milvia Casato British Journal of Haematology, 2025 Data S1. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
2023 International Rome consensus for the nomenclature of Sjögren disease Manuel Ramos-Casals, Alan N. Baer, María del Pilar Brito-Zerón, Katherine M. Hammitt, Coralie Bouillot, Soledad Retamozo, Alison Mackey, David Yarowsky, Breck Turner, Jaime Blanck, Benjamin A. Fisher, Esen K. Akpek, Chiara Baldini, Hendrika Bootsma, Simon J. Bowman, Thomas Dörner, Leslie Laing, Scott M. Lieberman, Xavier Mariette, Stephen C. Pflugfelder, Vidya Sankar, Antoni Sisó-Almirall, Athanasios G. Tzioufas, Juan-Manuel Anaya, Berkan Armağan, Michele Bombardieri, Steven Carsons, Salvatore de Vita, Robert I. Fox, Roberto Gerli, Roberto Giacomelli, Jacques Eric Gottenberg, Gabriela Hernández-Molina, Roland Jonsson, Aike Kruize, Seung-Ki Kwok, Xiaomei Li, Sara S. McCoy, Wan-Fai Ng, Peter Olsson, Maureen Rischmueller, Alain Saraux, R. Hal Scofield, Valéria Valim, Claudio Vitali, Frederick Vivino, Marie Wahren-Herlenius, Haralampos M. Moutsopoulos, , Miriam Akasbi, Alessia Alunno, Fabiola Atzeni, Elena Bartoloni, Stefano Bombardieri, Arthur Bookman, Francesco Carubbi, Sandra Consani- Fernández, Divi Cornec, Valerie Devauchelle-Pensec, Tamer A. Gheita, Andreas Goules, Benedikt Hofauer, Nevsun Inanc, Ciprian Jurcut, Clio P. Mavragani, Jacques Morel, Takashi Nakamura, Gaëtane Nocturne, Gunnel Nordmark, Sandra Gofinet Pasoto, Jacques-Olivier Pers, Sonja Praprotnik, Roberta Priori, Sandhya Pulukool, Luca Quartuccio, Astrid Rasmussen, Vasco C. Romão, Agata Sebastian, Raphaèle Seror, Roser Solans-Laqué, Yasunori Suzuki, Antonia Szanto, Virginia Fernandes Moça Trevisani, Arjan Vissink Nature Reviews Rheumatology, 2025
PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors C. Garufi, S. Mancuso, F. Ceccarelli, L. Caruso, C. Alessandri, M. Di Franco, R. Priori, V. Riccieri, R. Scrivo, S. Truglia, F. Conti, F.R. Spinelli Reumatismo, 2025 Objective. Patients Acceptable Symptom State (PASS) is a single dichotomized question assessing health satisfaction. We aimed to investigate PASS achievement within 4 weeks of treatment with Janus kinase (JAK) inhibitors (Jakinibs) and its association with treatment response after 4 and 12 weeks in rheumatoid arthritis (RA) patients. Methods. We recruited consecutive RA patients starting baricitinib or tofacitinib. At baseline, 4 and 12 weeks, we calculated disease activity [Disease Activity Score on 28 joints (DAS28), Clinical Disease Activity Index, Simplified Disease Activity Index], disease status [remission and low-disease activity (LDA)], percentage of patients achieving PASS, and the time to attain PASS. We assessed the impact of clinically relevant variables on PASS achievement by logistic regression analysis. Results. We enrolled 113 patients [98 (86.7%) females; median age 59.6 (interquartile range 16.9), median disease duration 144 (132) months]. 90 (79.6%) patients achieved PASS after 10 (8) days. A similar percentage of PASS achievers and non-achievers was in remission/LDA at weeks 4 and 12, but the reduction of disease activity was significantly greater in PASS achievers. All patients achieving Boolean remission at weeks 4 and 12 had achieved PASS within 4 weeks. The impact of Patients Global Assessment (PGA) on DAS28 was significantly greater in PASS non-achievers compared to PASS achievers; inversely, the impact of C-reactive protein was more relevant in PASS achievers. At multivariate analysis, pain and PGA were significantly associated with PASS. Conclusions. In our cohort, Jakinibs allowed an early achievement of PASS in a great percentage of RA patients. PASS is strictly dependent on PGA and pain and could suggest, early in the management of RA patients, therapeutic success.
Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with IgG4-related disease Linda Mastromanno, Federico Giardina, Angelica Gattamelata, Serena Colafrancesco, Simona Truglia, Francesca Romana Spinelli, Edoardo Simoncelli, Bruno Lucchino, Fabrizio Conti, Roberta Priori Reumatismo, 2025 Objective. To assess the adherence to the vaccination campaign against SARS-CoV-2 in patients with IgG4-related disease (IgG4-RD) and to evaluate the development of local and systemic adverse events (AEs) following vaccination. Additionally, to investigate the rate and outcome of SARS-CoV-2 infection in IgG4-RD patients. Methods. Patients with IgG4-RD in follow-up before the onset of the SARS-CoV-2 pandemic were contacted by telephone and asked to answer an ad hoc questionnaire regarding their vaccination status against SARS-CoV-2 and related AEs following vaccination. The occurrence and the outcome of SARS-CoV-2 infection were also recorded. The same questionnaire was proposed to healthy controls (HC). Results. 20 patients and 40 HC were enrolled. In the patient’s cohort, 90% were vaccinated with at least one dose; among them, 11 reported AEs: 61.1% systemic and 22.2% local. Within the HC group, 100% were vaccinated with at least one dose. 20 out of 40 HC had systemic AEs (50%), and 27 (67.5%) reported local AEs. Neither in IgG4-RD nor in HC, serious adverse reactions were observed. Among the patient’s cohort, 60% contracted SARS-CoV-2 infection, and 41.67% were on immunosuppressants at the time of the infection. One patient presented with severe COVID-19. No disease flares following vaccination or infection were reported. Conclusions. Results from our study indicate good adherence to the vaccination campaign against SARS-CoV-2 in patients with IgG4-RD and support a relatively good safety profile of this vaccine. Compared to controls, patients with IgG4-RD reported slightly more systemic AEs and fewer local AEs. A similar rate of COVID-19 development was observed between IgG4-RD patients and HC.
Identification of red flags for IgG4-related disease: an international European Reference Network for Rare Connective Tissue Diseases framework Emanuel Della-Torre, Rosaria Talarico, Jose Ballarin, Emanuele Bozzalla-Cassione, Chiara Cardamone, Cosimo Cigolini, Francesco Ferro, Tomas Fonseca, George E Fragoulis, Ilaria Galetti, Maria Gerosa, José Hernández-Rodríguez, Marco Lanzillotta, Diana Marinello, Thierry Martin, Fernando Martinez-Valle, Maria Maślińska, Michele Moretti, Marta Mosca, Ulf Müller-Ladner, Cecilia Nalli, Giovanni Orsolini, Cristina Pamfil, Guillermo Perez-Garcia, Roberta Priori, Giacomo Quattrocchio, Andreas Ramming, Francesca Regola, Vasco C Romão, Augusto Silva, Jan A M van Laar, Maria Jose Vicente-Edo, Shlomo Vinker, Tobias Alexander Lancet Rheumatology, 2025
Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus Piero Ruscitti, Yannick Allanore, Chiara Baldini, Giuseppe Barilaro, Elena Bartoloni Bocci, Pietro Bearzi, Elisa Bellis, Onorina Berardicurti, Alice Biaggi, Michele Bombardieri, Luca Cantarini, Francesco Paolo Cantatore, Roberto Caporali, Francesco Caso, Ricard Cervera, Francesco Ciccia, Paola Cipriani, Loukas Chatzis, Serena Colafrancesco, Fabrizio Conti, Erika Corberi, Luisa Costa, Damiano Currado, Maurizio Cutolo, Salvatore D'Angelo, Francesco Del Galdo, Ilenia Di Cola, Stefano Di Donato, Oliver Distler, Bernardo D'Onofrio, Andrea Doria, Bruno Fautrel, Serena Fasano, Eugen Feist, Benjamin A. Fisher, Marco Gabini, Saviana Gandolfo, Mariele Gatto, Irene Genovali, Roberto Gerli, Rosa Daniela Grembiale, Giuliana Guggino, Anna Maria Hoffmann-Vold, Annamaria Iagnocco, Francesco Salvatore Iaquinta, Vasiliki Liakouli, Menelaos N. Manoussakis, Annalisa Marino, Daniele Mauro, Carlomaurizio Montecucco, Marta Mosca, Saverio Naty, Luca Navarini, Daniele Occhialini, Valeria Orefice, Federico Perosa, Carlo Perricone, Andrea Pilato, Costantino Pitzalis, Elena Pontarini, Marcella Prete, Roberta Priori, Felice Rivellese, Piercarlo Sarzi-Puttini, Raffaele Scarpa, Giandomenico Sebastiani, Carlo Selmi, Yehuda Shoenfeld, Giovanni Triolo, Francesca Trunfio, Qingran Yan, Athanasios G. Tzioufas, Roberto Giacomelli Autoimmunity Reviews, 2024
Influence of exposure to climate-related hazards in the phenotypic expression of primary Sjögren’s syndrome Alejandra Flores-Chávez, Pilar Brito-Zerón, Wan-Fai Ng, Antónia Szántó, Astrid Rasmussen, Roberta Priori, Chiara Baldini, Berkan Armagan, Burcugül Özkiziltaş, Sonja Praprotnik, Yasunori Suzuki, Luca Quartuccio, Gabriela Hernández-Molina, Nevsun Inanc, Elena Bartoloni, Maureen Rischmueller, Fabiola Reis-de Oliveira, Virginia Fernandes Moça Trevisani, Ciprian Jurcut, Gunnel Nordmark, Francesco Carubbi, Benedikt Hofauer, Valeria Valim, Sandra G. Pasoto, Soledad Retamozo, Fabiola Atzeni, Eva Fonseca-Aizpuru, Miguel López-Dupla, Roberto Giacomelli, Hideki Nakamura, Miriam Akasbi, Kyle Thompson, Ildiko Fanny Horváth, A. Darise Farris, Edoardo Simoncelli, Stefano Bombardieri, Levent Kilic, Abdurrahman Tufan, Katja Perdan Pirkmajer, Yuhei Fujisawa, Salvatore De Vita, Kerem Abacar, Manuel Ramos-Casals Clinical and Experimental Rheumatology, 2023
Exposure to air pollution as an environmental determinant of how Sjögren’s disease is expressed at diagnosis Clinical and Experimental Rheumatology, 2023
Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission Roberto Giacomelli, Roberto Caporali, Francesco Ciccia, Serena Colafrancesco, Lorenzo Dagna, Marcello Govoni, Florenzo Iannone, Pietro Leccese, Carlomaurizio Montecucco, Giovanni Pappagallo, Giovanni Pistone, Roberta Priori, Piero Ruscitti, Paolo Sfriso, Luca Cantarini, Norma Belfiore, Cristina Bernardi, Marco Gabini, Silvano Bettio, Antonio Brucato, Giovanni Italiano, Francesco Paolo Cantatore, Daniela Iacono, Ilenia Pantano, Enrico Tirri, Francesco Ursini, Andrea Lo Monaco, Francesco Caso, Luca Quartuccio, Maria Sole Chimenti, Angelica Gattamelata, Elisa Gremese, Marino Paroli, Andrea Picchianti-Diamanti, Gian Domenico Sebastiani, Ennio Favalli, Alberto Sulli, Micol Frassi, Paola Faggioli, Rosario Foti, Corrado Campochiaro, Giulio Cavalli, Alessandro Tomelleri, Maria Manara, Ludovico De Stefano, Rossella De Angelis, Simone Parisi, Giuseppe Lopalco, Matteo Piga, Daniela Marotto, Michele Colaci, Angela Padula, Giuliana Guggino, Giacomo Emmi, Chiara Baldini, Jurgen Sota, Antonio Vitale, Alvise Berti, Elena Bartoloni, Chiara Grava, Sara Bindoli, Rosetta Vitetta Autoimmunity Reviews, 2023
Age at diagnosis influences the clinical phenotype, treatment strategies and outcomes in patients with giant cell arteritis: results from the observational GCAGE study on a large cohort of 1004 patients Sara Monti, Alessandra Milanesi, Catherine Klersy, Alessandro Tomelleri, Lorenzo Dagna, Corrado Campochiaro, Nicola Farina, Francesco Muratore, Elena Galli, Chiara Marvisi, Milena Bond, Alvise Berti, Roberto Bortolotti, Roberto Padoan, Franco Schiavon, Mara Felicetti, Carlotta Nannini, Fabrizio Cantini, Alessandro Giollo, Maurizio Rossini, Edoardo Conticini, Bruno Frediani, Fabrizio Conti, Roberta Priori, Marco Sebastiani, Giulia Cassone, Luca Quartuccio, Elena Treppo, Silvano Bettio, Ariela Hoxha, Marco Lovisotto, Giacomo Emmi, Irene Mattioli, Pietro Leccese, Roberto Caporali, Lorenza Maria Argolini, Rosario Foti, Elisa Visalli, Michele Colaci, Carlo Salvarani, Carlomaurizio Montecucco Annals of the Rheumatic Diseases, 2023
Mortality risk factors in primary Sjögren syndrome: a real-world, retrospective, cohort study Pilar Brito-Zerón, Alejandra Flores-Chávez, Ildiko Fanny Horváth, Astrid Rasmussen, Xiaomei Li, Peter Olsson, Arjan Vissink, Roberta Priori, Berkan Armagan, Gabriela Hernandez-Molina, Sonja Praprotnik, Luca Quartuccio, Nevsun Inanç, Burcugül Özkızıltaş, Elena Bartoloni, Agata Sebastian, Vasco C. Romão, Roser Solans, Sandra G. Pasoto, Maureen Rischmueller, Carlos Galisteo, Yasunori Suzuki, Virginia Fernandes Moça Trevisani, Cecilia Fugmann, Andrés González-García, Francesco Carubbi, Ciprian Jurcut, Toshimasa Shimizu, Soledad Retamozo, Fabiola Atzeni, Benedikt Hofauer, Sheila Melchor-Díaz, Tamer Gheita, Miguel López-Dupla, Eva Fonseca-Aizpuru, Roberto Giacomelli, Marcos Vázquez, Sandra Consani, Miriam Akasbi, Hideki Nakamura, Antónia Szántó, A. Darise Farris, Li Wang, Thomas Mandl, Angelica Gattamelata, Levent Kilic, Katja Perdan Pirkmajer, Kerem Abacar, Abdurrahman Tufan, Salvatore de Vita, Hendrika Bootsma, Manuel Ramos-Casals, S. Arends, E. Treppo, S. Longhino, V. Manfrè, M. Rizzo, C. Baldini, S. Bombardieri, M. Bandeira, M. Silvéiro-António, R. Seror, X. Mariette, G. Nordmark, D. Danda, P. Wiland, R. Gerli, S.K. Kwok, S.H. Park, M. Kvarnstrom, M. Wahren-Herlenius, S. Downie-Doyle, D. Sene, D. Isenberg, V. Valim, V. Devauchelle-Pensec, A. Saraux, J. Morel, C. Morcillo, P.E. Díaz Cuiza, B.E. Herrera, L. González-de-Paz, A. Sisó-Almirall Eclinicalmedicine, 2023
Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies Gabriela Hernández-Molina, Belchin Kostov, Pilar Brito-Zerón, Arjan Vissink, Thomas Mandl, Anneline C Hinrichs, Luca Quartuccio, Chiara Baldini, Raphaele Seror, Antonia Szántó, David Isenberg, Roberto Gerli, Gunnel Nordmark, Astrid Rasmussen, Roser Solans-Laque, Benedikt Hofauer, Damien Sène, Sandra G Pasoto, Maureen Rischmueller, Sonja Praprotnik, Tamer A Gheita, Debashish Danda, Berkan Armağan, Yasunori Suzuki, Valeria Valim, Valerie Devauchelle-Pensec, Soledad Retamozo, Marika Kvarnstrom, Agata Sebastian, Fabiola Atzeni, Roberto Giacomelli, Steven E Carsons, Seung-Ki Kwok, Hideki Nakamura, Virginia Fernandes Moça Trevisani, Alejandra Flores-Chávez, Xavier Mariette, Manuel Ramos-Casals, P Brito-Zerón, A Flores-Chávez, M Ramos-Casals, I F Horvath, A Szántó, T Tarr, F Ng, A Rasmussen, D A Farris, X Dong, Z Yan, X Li, B Xu, C Baldini, S Bombardieri, T Mandl, P Olsson, R Priori, F Giardina, R Izzo, R Seror, X Mariette, J E Gottenberg, A A Kruize, A Hinrichs, H Bootsma, A Vissink, D Danda, P Sandhya, G Hernandez-Molina, J Sánchez-Guerrero, B Armagan, L Kilic, U Kalyoncu, L Quartuccio, S Gandolfo, S De Vita, S Praprotnik, A Sebastian, P Wiland, R Gerli, E Bartoloni, S-K Kwok, S-H Park, M Kvarnstrom, M Wahren-Herlenius, M Rischmueller, S Downie-Doyle, R Solans-Laque, D Sene, S G Pasoto, Y Suzuki, M Kawano, D A Isenberg, G Nordmark, V Valim, H Nakamura, T Shimizu, S -Y Nishihata, T Nakamura, Y Takagi, V Fernandes Moça Trevisani, S Retamozo, B Hofauer, A Knopf, G Fraile, R Giacomelli, , V Devauchelle-Pensec, A Saraux, M Bombardieri, E Astorri, F Atzeni, D Hammenfors, J G Brun, S E Carsons, B Maure Noia, A B Argibay Filgueira, T A Gheita, I Sánchez Berná, M López Dupla, R Alberto Rojas, A M Febrer Nafria, J Morel, E Fonseca Aizpuru, S Santos Seoane, P Brito-Zerón, C Morcillo, S Melchor Díaz, P Carreira, C Vollenveider, M Vázquez, P Ericka Díaz Cuiza, B E Herrera, S Andrea Consani, A Comotto, B de Miguel Campo, B Kostov, A Sisó-Almirall, B Kostov, N Acar-Denizli, and Rheumatology United Kingdom, 2023
Maladaptive Autophagy in the Pathogenesis of Autoimmune Epithelitis in Sjögren's Syndrome Serena Colafrancesco, Cristiana Barbati, Roberta Priori, Erisa Putro, Federico Giardina, Angelica Gattamelata, Benedetta Monosi, Tania Colasanti, Alessandra Ida Celia, Bruna Cerbelli, Carla Giordano, Susanna Scarpa, Massimo Fusconi, Giulio Cavalli, Onorina Berardicurti, Saviana Gandolfo, Saba Nayar, Francesca Barone, Roberto Giacomelli, Salvatore De Vita, Cristiano Alessandri, Fabrizio Conti Arthritis and Rheumatology, 2022
Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts Vasileios C. Pezoulas, Andreas Goules, Fanis Kalatzis, Luke Chatzis, Konstantina D. Kourou, Aliki Venetsanopoulou, Themis P. Exarchos, Saviana Gandolfo, Konstantinos Votis, Evi Zampeli, Jan Burmeister, Thorsten May, Manuel Marcelino Pérez, Iryna Lishchuk, Thymios Chondrogiannis, Vassiliki Andronikou, Theodora Varvarigou, Nenad Filipovic, Manolis Tsiknakis, Chiara Baldini, Michele Bombardieri, Hendrika Bootsma, Simon J. Bowman, Muhammad Shahnawaz Soyfoo, Dorian Parisis, Christine Delporte, Valérie Devauchelle-Pensec, Jacques-Olivier Pers, Thomas Dörner, Elena Bartoloni, Roberto Gerli, Roberto Giacomelli, Roland Jonsson, Wan-Fai Ng, Roberta Priori, Manuel Ramos-Casals, Kathy Sivils, Fotini Skopouli, Witte Torsten, Joel A. G. van Roon, Mariette Xavier, Salvatore De Vita, Athanasios G. Tzioufas, Dimitrios I. Fotiadis Computational and Structural Biotechnology Journal, 2022
Resilience in women with primary Sjögren’s syndrome Roberta Priori, Federico Giardina, Raffaella Izzo, Angelica Gattamelata, Massimo Fusconi, Serena Colafrancesco, Giuseppe Curcio Rheumatology International, 2021
Childhood-onset of primary Sjögren's syndrome: Phenotypic characterization at diagnosis of 158 children Manuel Ramos-Casals, Nihan Acar-Denizli, Arjan Vissink, Pilar Brito-Zerón, Xiaomei Li, Francesco Carubbi, Roberta Priori, Nataša Toplak, Chiara Baldini, Enrique Faugier-Fuentes, Aike A Kruize, Thomas Mandl, Minako Tomiita, Saviana Gandolfo, Kunio Hashimoto, Gabriela Hernandez-Molina, Benedikt Hofauer, Samara Mendieta-Zerón, Astrid Rasmussen, Pulukool Sandhya, Damien Sene, Virginia Fernandes Moça Trevisani, David Isenberg, Erik Sundberg, Sandra G Pasoto, Agata Sebastian, Yasunori Suzuki, Soledad Retamozo, Bei Xu, Roberto Giacomelli, Angelica Gattamelata, Masa Bizjak, Stefano Bombardieri, Richard-Eduardo Loor-Chavez, Anneline Hinrichs, Peter Olsson, Hendrika Bootsma, Scott M Lieberman, B Kostov, I -F Horvath, A Szanto, R Seror, X Mariette, M Kvarnstrom, M Wahren-Herlenius, S Praprotnik, R Solans, G Nordmark, D Hammenfors, J G Brun, T A Gheita, F Atzeni, B Armagan, L Kilic, U Kalyoncu, T Nakamura, Y Takagi, S Consani, F Olivera Solorzano, and Rheumatology United Kingdom, 2021
SARS-CoV-2 infection in patients with primary Sjögren syndrome: Characterization and outcomes of 51 patients Pilar Brito-Zerón, Sheila Melchor, Raphaèle Seror, Roberta Priori, Roser Solans, Belchin Kostov, Chiara Baldini, Francesco Carubbi, Jose Luis Callejas, Pablo Guisado-Vasco, Gabriela Hernández-Molina, Sandra G Pasoto, Valeria Valim, Antoni Sisó-Almirall, Xavier Mariette, Patricia Carreira, Manuel Ramos-Casals, P Brito-Zerón, C Morcillo, P Brito-Zerón, A Flores-Chávez, M Ramos-Casals, N Acar-Denizli, I F Horvath, A Szanto, T Tarr, R Seror, X Mariette, T Mandl, P Olsson, X Li, B Xu, C Baldini, S Bombardieri, J E Gottenberg, S Gandolfo, S De Vita, R Priori, F Giardina, G Hernandez-Molina, J Sánchez-Guerrero, A A Kruize, A Hinrichs, V Valim, D Isenberg, R Solans, M Rischmueller, S Downie-Doyle, S-K Kwok, S-H Park, G Nordmark, Y Suzuki, M Kawano, R Giacomelli, V Devauchelle-Pensec, A Saraux, B Hofauer, A Knopf, H Bootsma, A Vissink, J Morel, C Vollenveider, F Atzeni, S Retamozo, V Moça Trevisano, B Armagan, L Kilic, U Kalyoncu, S G Pasoto, B Kostov, A Sisó-Almirall, S Consani-Fernández, F Carubbi, J L Callejas, M López-Dupla, R Pérez-Alvarez, M Akasbi, P Guisado-Vasco, I Sánchez, and Rheumatology United Kingdom, 2021
Effectiveness and safety of baricitinib in rheumatoid arthritis: A monocentric, longitudinal, real-life experience Clinical and Experimental Rheumatology, 2021
Risk of acute arterial and venous thromboembolic events in eosinophilic granulomatosis with polyangiitis (Churg–Strauss syndrome) Alessandra Bettiol, Renato Alberto Sinico, Franco Schiavon, Sara Monti, Enrica Paola Bozzolo, Franco Franceschini, Marcello Govoni, Claudio Lunardi, Giuseppe Guida, Giuseppe Lopalco, Giuseppe Paolazzi, Angelo Vacca, Gina Gregorini, Pietro Leccese, Matteo Piga, Fabrizio Conti, Paolo Fraticelli, Luca Quartuccio, Federico Alberici, Carlo Salvarani, Silvano Bettio, Simone Negrini, Carlo Selmi, Savino Sciascia, Gabriella Moroni, Loredana Colla, Carlo Manno, Maria Letizia Urban, Alfredo Vannacci, Maria Rosa Pozzi, Paolo Fabbrini, Stefano Polti, Mara Felicetti, Maria Rita Marchi, Roberto Padoan, Paolo Delvino, Roberto Caporali, Carlomaurizio Montecucco, Lorenzo Dagna, Adriana Cariddi, Paola Toniati, Silvia Tamanini, Federica Furini, Alessandra Bortoluzzi, Elisa Tinazzi, Lorenzo Delfino, Iuliana Badiu, Giovanni Rolla, Vincenzo Venerito, Florenzo Iannone, Alvise Berti, Roberto Bortolotti, Vito Racanelli, Guido Jeannin, Angela Padula, Alberto Cauli, Roberta Priori, Armando Gabrielli, Milena Bond, Martina Tedesco, Giulia Pazzola, Paola Tomietto, Marco Pellecchio, Chiara Marvisi, Federica Maritati, Alessandra Palmisano, Christian Dejaco, Johann Willeit, Stefan Kiechl, Iacopo Olivotto, Peter Willeit, Domenico Prisco, Augusto Vaglio, Giacomo Emmi European Respiratory Journal, 2021
“Protenuria in SLE: Is it always lupus?” Alessandra Ida Celia, Roberta Priori, Bruna Cerbelli, Francesca Diomedi-Camassei, Vincenzo Leuzzi, Rossana Scrivo, Cristiano Alessandri, Giulia d’Amati, Fabrizio Conti Lupus, 2021
The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus Roberto Giacomelli, Antonella Afeltra, Elena Bartoloni, Onorina Berardicurti, Michele Bombardieri, Alessandra Bortoluzzi, Francesco Carubbi, Francesco Caso, Ricard Cervera, Francesco Ciccia, Paola Cipriani, Emmanuel Coloma-Bazán, Fabrizio Conti, Luisa Costa, Salvatore D’Angelo, Oliver Distler, Eugen Feist, Nathan Foulquier, Marco Gabini, Vanessa Gerber, Roberto Gerli, Rosa Daniela Grembiale, Giuliana Guggino, Ariela Hoxha, Annamaria Iagnocco, Suzana Jordan, Bashar Kahaleh, Kim Lauper, Vasiliki Liakouli, Ennio Lubrano, Domenico Margiotta, Saverio Naty, Luca Navarini, Federico Perosa, Carlo Perricone, Roberto Perricone, Marcella Prete, Jacques-Olivier Pers, Costantino Pitzalis, Roberta Priori, Felice Rivellese, Amelia Ruffatti, Piero Ruscitti, Raffaele Scarpa, Yehuda Shoenfeld, Giovanni Triolo, Athanasios Tzioufas Autoimmunity Reviews, 2021
What about glucocorticoids in primary Sjögren's syndrome? Clinical and Experimental Rheumatology, 2021
Significance of anti-La/SSB antibodies in primary Sjögren's syndrome patients with combined positivity for anti-Ro/SSA and salivary gland biopsy Clinical and Experimental Rheumatology, 2021
Validation of thymic stromal lymphopoietin as a biomarker of primary Sjögren's syndrome and related lymphoproliferation: Results in independent cohorts Clinical and Experimental Rheumatology, 2021
Post-COVID-19 syndrome in patients with primary Sjögren's syndrome after acute SARS-CoV-2 infection Clinical and Experimental Rheumatology, 2021
Influence of the age at diagnosis in the disease expression of primary Sjögren's syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium Clinical and Experimental Rheumatology, 2021
An exploratory cross-sectional study of subclinical vascular damage in patients with polymyalgia rheumatica Rossana Scrivo, Valeria Silvestri, Francesco Ciciarello, Paola Sessa, Iolanda Rutigliano, Cristina Sestili, Giuseppe La Torre, Cristiana Barbati, Alessio Altobelli, Cristiano Alessandri, Fulvia Ceccarelli, Manuela Di Franco, Roberta Priori, Valeria Riccieri, Antonio Sili Scavalli, Francesca Romana Spinelli, Luciano Agati, Francesco Fedele, Bruno Gossetti, Fabrizio Conti, Guido Valesini Scientific Reports, 2020
Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma Elena Pontarini, William James Murray-Brown, Cristina Croia, Davide Lucchesi, James Conway, Felice Rivellese, Liliane Fossati-Jimack, Elisa Astorri, Edoardo Prediletto, Elisa Corsiero, Francesca Romana Delvecchio, Rachel Coleby, Eva Gelbhardt, Aurora Bono, Chiara Baldini, Ilaria Puxeddu, Piero Ruscitti, Roberto Giacomelli, Francesca Barone, Benjamin Fisher, Simon J Bowman, Serena Colafrancesco, Roberta Priori, Nurhan Sutcliffe, Stephen Challacombe, Gianluca Carlesso, Anwar Tappuni, Costantino Pitzalis, Michele Bombardieri Annals of the Rheumatic Diseases, 2020
Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies Clinical and Experimental Rheumatology, 2020
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes Antonio Vitale, Giulio Cavalli, Piero Ruscitti, Jurgen Sota, Serena Colafrancesco, Roberta Priori, Guido Valesini, Lorenza Maria Argolini, Elena Baldissera, Elena Bartoloni, Daniele Cammelli, Giovanni Canestrari, Elena Cavallaro, Maria Grazia Massaro, Paola Cipriani, Ginevra De Marchi, Salvatore De Vita, Giacomo Emmi, Micol Frassi, Roberto Gerli, Elisa Gremese, Florenzo Iannone, Marco Fornaro, Anna Paladini, Giuseppe Lopalco, Raffaele Manna, Alessandro Mathieu, Carlomaurizio Montecucco, Marta Mosca, Ilaria Piazza, Matteo Piga, Irene Pontikaki, Micol Romano, Silvia Rossi, Maurizio Rossini, Elena Silvestri, Chiara Stagnaro, Rosaria Talarico, Bruno Frediani, Angela Tincani, Ombretta Viapiana, Gianfranco Vitiello, Paola Galozzi, Paolo Sfriso, Carla Gaggiano, Salvatore Grosso, Donato Rigante, Lorenzo Dagna, Roberto Giacomelli, Luca Cantarini Frontiers in Medicine, 2020
CXCL13 as biomarker for histological involvement in Sjögren's syndrome Serena Colafrancesco, Roberta Priori, Charlotte G Smith, Antonina Minniti, Valentina Iannizzotto, Elena Pipi, Davide Lucchesi, Elena Pontarini, Saba Nayar, Joana Campos, Francesca Arienzo, Massimo Fusconi, Bruna Cerbelli, Carla Giordano, Guido Valesini, Michele Bombardieri, Benjamin A Fisher, Francesca Barone Rheumatology United Kingdom, 2020
First Report of the Italian Registry on Immune-Mediated Congenital Heart Block (Lu.Ne Registry) Micaela Fredi, Laura Andreoli, Beatrice Bacco, Tiziana Bertero, Alessandra Bortoluzzi, Silvia Breda, Veronica Cappa, Fulvia Ceccarelli, Rolando Cimaz, Salvatore De Vita, Emma Di Poi, Elena Elefante, Franco Franceschini, Maria Gerosa, Marcello Govoni, Ariela Hoxha, Andrea Lojacono, Luca Marozio, Alessandro Mathieu, Pier Luigi Meroni, Antonina Minniti, Marta Mosca, Marina Muscarà, Melissa Padovan, Matteo Piga, Roberta Priori, Véronique Ramoni, Amelia Ruffatti, Chiara Tani, Marta Tonello, Laura Trespidi, Sonia Zatti, Stefano Calza, Angela Tincani, Antonio Brucato Frontiers in Cardiovascular Medicine, 2019
Phosphatidylinositol 3-kinase delta pathway: A novel therapeutic target for Sjögren's syndrome Saba Nayar, Joana Campos, Charlotte G Smith, Valentina Iannizzotto, David H Gardner, Serena Colafrancesco, Elena Pipi, Florian Kollert, Kelly J Hunter, Charlotte Brewer, Christopher Dominic Buckley, Simon J Bowman, Roberta Priori, Guido Valesini, Maria Juarez, William A Fahy, Benjamin A Fisher, Andrew Payne, Rodger A Allen, Francesca Barone Annals of the Rheumatic Diseases, 2019
Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease Jurgen Sota, Donato Rigante, Piero Ruscitti, Antonella Insalaco, Paolo Sfriso, Salvatore de Vita, Rolando Cimaz, Giuseppe Lopalco, Giacomo Emmi, Francesco La Torre, Claudia Fabiani, Alma Nunzia Olivieri, Marco Cattalini, Daniele Cammelli, Romina Gallizzi, Maria Alessio, Raffaele Manna, Ombretta Viapiana, Micol Frassi, Manuela Pardeo, Armin Maier, Carlo Salvarani, Rosaria Talarico, Marta Mosca, Serena Colafrancesco, Roberta Priori, Maria Cristina Maggio, Carla Gaggiano, Salvatore Grosso, Fabrizio De Benedetti, Antonio Vitale, Roberto Giacomelli, Luca Cantarini Frontiers in Pharmacology, 2019
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis Roberto Giacomelli, Antonella Afeltra, Alessia Alunno, Elena Bartoloni-Bocci, Onorina Berardicurti, Michele Bombardieri, Alessandra Bortoluzzi, Roberto Caporali, Francesco Caso, Ricard Cervera, Maria Sole Chimenti, Paola Cipriani, Emmanuel Coloma, Fabrizio Conti, Salvatore D’Angelo, Salvatore De Vita, Salvatore Di Bartolomeo, Oliver Distler, Andrea Doria, Eugen Feist, Benjamin A. Fisher, Maria Gerosa, Michele Gilio, Giuliana Guggino, Vasiliki Liakouli, Domenico Paolo Emanuele Margiotta, Pierluigi Meroni, Gianluca Moroncini, Federico Perosa, Marcella Prete, Roberta Priori, Chiara Rebuffi, Piero Ruscitti, Raffaele Scarpa, Yehuda Shoenfeld, Monica Todoerti, Francesco Ursini, Guido Valesini, Serena Vettori, Claudio Vitali, Athanasios G. Tzioufas Autoimmunity Reviews, 2019
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response Antonio Vitale, Giulio Cavalli, Serena Colafrancesco, Roberta Priori, Guido Valesini, Lorenza Maria Argolini, Elena Baldissera, Elena Bartoloni, Daniele Cammelli, Giovanni Canestrari, Jurgen Sota, Elena Cavallaro, Maria Grazia Massaro, Piero Ruscitti, Paola Cipriani, Ginevra De Marchi, Salvatore De Vita, Giacomo Emmi, Gianfranco Ferraccioli, Micol Frassi, Roberto Gerli, Elisa Gremese, Florenzo Iannone, Giovanni Lapadula, Giuseppe Lopalco, Raffaele Manna, Alessandro Mathieu, Carlomaurizio Montecucco, Marta Mosca, Ilaria Piazza, Matteo Piga, Irene Pontikaki, Micol Romano, Silvia Rossi, Maurizio Rossini, Elena Silvestri, Chiara Stagnaro, Rosaria Talarico, Angela Tincani, Ombretta Viapiana, Gianfranco Vitiello, Paola Galozzi, Paolo Sfriso, Carla Gaggiano, Donato Rigante, Lorenzo Dagna, Roberto Giacomelli, Luca Cantarini Frontiers in Pharmacology, 2019
Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients Clinical and Experimental Rheumatology, 2019
The Big Data Sjögren consortium: A project for a new data science era Clinical and Experimental Rheumatology, 2019
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study for the “Working Group” of Systemic Autoinflammatory Diseases of SIR (Italian Society of Rheumatology), Jurgen Sota, Antonio Vitale, Antonella Insalaco, Paolo Sfriso, Giuseppe Lopalco, Giacomo Emmi, Marco Cattalini, Raffaele Manna, Rolando Cimaz, Roberta Priori, Rosaria Talarico, Ginevra de Marchi, Micol Frassi, Romina Gallizzi, Alessandra Soriano, Maria Alessio, Daniele Cammelli, Maria Cristina Maggio, Stefano Gentileschi, Renzo Marcolongo, Francesco La Torre, Claudia Fabiani, Serena Colafrancesco, Francesca Ricci, Paola Galozzi, Ombretta Viapiana, Elena Verrecchia, Manuela Pardeo, Lucia Cerrito, Elena Cavallaro, Alma Nunzia Olivieri, Giuseppe Paolazzi, Gianfranco Vitiello, Armin Maier, Elena Silvestri, Chiara Stagnaro, Guido Valesini, Marta Mosca, Salvatore de Vita, Angela Tincani, Giovanni Lapadula, Bruno Frediani, Fabrizio De Benedetti, Florenzo Iannone, Leonardo Punzi, Carlo Salvarani, Mauro Galeazzi, Rossella Angotti, Mario Messina, Gian Marco Tosi, Donato Rigante, Luca Cantarini Clinical Rheumatology, 2018
Letters to the editor Roberta Priori, Bruno Lucchino, Bruna Cerbelli, Cristiano Alessandri, Valeria Bottaro, et al. Rheumatology United Kingdom, 2018
How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: Analysis of 10,500 patients (Sjögren Big Data Project) Clinical and Experimental Rheumatology, 2018
A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: A nationwide multi-center retrospective observational study Antonio Vitale, Antonella Insalaco, Paolo Sfriso, Giuseppe Lopalco, Giacomo Emmi, Marco Cattalini, Raffaele Manna, Rolando Cimaz, Roberta Priori, Rosaria Talarico, Stefano Gentileschi, Ginevra de Marchi, Micol Frassi, Romina Gallizzi, Alessandra Soriano, Maria Alessio, Daniele Cammelli, Maria C. Maggio, Renzo Marcolongo, Francesco La Torre, Claudia Fabiani, Serena Colafrancesco, Francesca Ricci, Paola Galozzi, Ombretta Viapiana, Elena Verrecchia, Manuela Pardeo, Lucia Cerrito, Elena Cavallaro, Alma N. Olivieri, Giuseppe Paolazzi, Gianfranco Vitiello, Armin Maier, Elena Silvestri, Chiara Stagnaro, Guido Valesini, Marta Mosca, Salvatore de Vita, Angela Tincani, Giovanni Lapadula, Bruno Frediani, Fabrizio De Benedetti, Florenzo Iannone, Leonardo Punzi, Carlo Salvarani, Mauro Galeazzi, Donato Rigante, Luca Cantarini Frontiers in Pharmacology, 2016
New Biological Avenues for Sjögren's Syndrome R. Priori, S. Colafrancesco, G. Valesini, F. Barone Sjogren S Syndrome Novel Insights in Pathogenic Clinical and Therapeutic Aspects, 2016
Fatigue and widespread pain in systemic lupus erythematosus and sjögren's syndrome: Symptoms of inflammatory disease or associated fibromyalgia? Clinical and Experimental Rheumatology, 2012
Adult-onset Still's disease: Not always so good Clinical and Experimental Rheumatology, 2012
Uveitis with retinal occlusive vasculitis and sensorineural hypoacusia as first symptoms of relapsing polychondritis Clinical and Experimental Rheumatology, 2012
Decreased immunoreactive beta-endorphin in mononuclear leucocytes from patients with chronic fatigue syndrome Clinical and Experimental Rheumatology, 1998
Differential risk of non-Hodgkin's lymphoma in Italian patients with primary Sjogren's syndrome Journal of Rheumatology, 1997
Relapsing polychondritis: A syndrome rather than a distinct clinical entity ? [2] Clinical and Experimental Rheumatology, 1997
Interferon α for ocular Behcet's disease Paola Pivetti‐Pezzi, Massimo Accorinti, Maria Pia Pirraglia, Roberta Priori, Guido Valesini Acta Ophthalmologica Scandinavica, 1997
Cardiac involvement in behçet’s disease Sergio Morelli, Claudio Perrone, Luigi Ferrante, Alessandro Sgreccia, Roberta Priori, et al. Cardiology Switzerland, 1997
Anti-cardiolipin antibodies in HIV infection are true antiphospholipids not associated with antiphospholipid syndrome Annali Italiani Di Medicina Interna, 1993
